Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Iambic Therapeutics
Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of Both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting
March 28, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors
March 27, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures
February 12, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Expands Leadership Team With the Appointment of Neil Josephson, MD as Chief Medical Officer
February 09, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA
October 03, 2023
From
Iambic Therapeutics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.